Gemcitabine and radiosensitization in human tumor cells

Investigational New Drugs

Volumn 14, Issue 3, 1996, Pages 257-263

  Shewach, Donna S ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Chemotherapy; Gemcitabine; Human tumor cells; Radiation; Radiosensitization

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CYTOTOXICITY; DNA REPLICATION; DNA SYNTHESIS; DOSE TIME EFFECT RELATION; ENZYME INHIBITION; HEAD AND NECK CANCER; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; SOLID TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL SURVIVAL; CLINICAL TRIALS; DEOXYCYTIDINE; DEOXYRIBONUCLEOTIDES; DNA; HUMANS; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0029805849     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00194528     Document Type: Review

References (52)

1. Abbruzzese JL, Grunewald R, Weeks EA et al.: A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
2. Poplin EA, Corbett T, Flaherty L et al.: Difluorodeoxycytidine (dFdC)-gemcitabine. A phase I study. Invest New Drugs 10:165-170, 1992
3. Lund B, Kristjansen PEG, Hansen HH: Clinical and preclinical activity of 2′,2′difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45-55, 1993
4. Hertel LW, Kroin JS, Misner JW, Tustin JM: Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53:2406-2409, 1988
5. Hertel LW, Boder GB, Kroin JS et al.: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′deoxycytidine). Cancer Res 50:4417-4422, 1990
6. Heinemann B, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′2′-difluorodeoxycytidine and 1-Darabinofuranosylcytosine. Cancer Res 48:4024-4031, 1988
7. Merriman RL, Schultz RM, Hertel LW et al.: Evaluation of the antitumor activity of gemcitabine against human carcinoma xenografts. Proc Am Assoc Cancer Res 35:448, 1994
8. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GJ: Improved antitumor effect of 2′,2′-difluorodeoxycytidine (Gemcitabine) in murine colon carcinomas, when administered as continuous infusions. Proc Am Assoc Cancer Res 35:447, 1994
9. Braakhuis BJM, Dongen GAMS, Vermorken JB, Snow GB: Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51:211-214, 1994
10. Grunewald R, Kantarjian H, Du M et al.: Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406-413, 1992
11. DeVita VT, Hellman S, Rosenberg SA: In: Cancer Principles and Practice of Oncology, 3rd edition. Lippincott, Philadelphia, 1989
12. Kaye SB: Gemcitabine: current status of phase I and II trials. J Clin Oncol 12:1527-1531, 1994
13. Fossella FV, Lippman SM, Tarassoff P: Phase I/II study of gemcitabine, an active agent for advanced non-small cell lung cancer(NSCLC). Proc Am Soc Clin Oncol 14:371 (abstr1144), 1995
14. Carmichael J, Possinger K, Phillip P et al.: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol (in press)
15. Lund B, Hansen OP, Theilade K et al.: Phase II study of gemcitabine (2′ ,2′-difluorodeoxycytidine) in previously treated ovarian cancer. J Nat Cancer Inst 86:1530-1533, 1994
16. Moore M, Andersen J, Burris H et al.: A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 14:199(abstr 473), 1995
17. Anderson H, Lund B, Bach F et al.: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer. A phase II study. J Clin Oncol 12:1821-1826, 1994
18. Szybalski W: X-ray sensitization by halopyrimidines. Cancer Chemother Reports 58:539-557, 1974
19. Kim JH, Alfieri AA, Kim SH, Fuks Z: The potentiation of radiation response on murine tumor by fludarabine phosphate. Cancer Lett 31:69-76, 1986
20. Iliakis G, Seaner P: Differences in inhibition by betaarabinofuranosyladenine (araA) of radiation induced DNA damage repair in exponentially growing and plateau-phase CHO cells. Radiat Environ Biol Phys 27:295-305, 1988
21. Bruso CE, Shewac DS, Lawrence TS: Fluorodeoxyuridine-induced radiosensitization and inhibition of NA double strand break repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 19:1411-1417, 1990
22. Gregoire V, Hunter N, Milas L et al.: Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res 54:468-474, 1994
23. Rockwell S, Grindey GB: Effect of 2′,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res 4:151-155, 1992
24. Shewach DS, Hahn TM, Chang E et al.: Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218-3223, 1994
25. Ruiz van Haperen VWT, Veerman G, Boven E et al.: Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Pharmacol 48:1327-1339, 1994
26. Ruiz van Haperen VWT, Veerman G, Eriksson S et al.: Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54:4138-4143, 1994
27. Shewach DS, Reynolds KK, Hertel LW: Nucleotide specificity of deoxycytidine kinase. Mol Pharmacol 42:518-524, 1992
28. Grunewald R, Kanatarjian H, Keating MJ et al.: Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823-6826, 1990
29. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W: Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during aphase I trial of gemcitabine. Cancer Chemother Pharmacol 27:285-292, 1991
30. Heinemann V, Xu Y-Z, Chubb S et al.: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52:53-539, 1991
31. Xu Y-Z, Plunkett W: Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 44:1819-1827, 1992
32. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GJ: ′,2′-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 46:762-766, 1993
33. Huang P, Chubb S, Hertel LW et al.: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991
34. Ross DD, Cuddy DP: Molecular effects of 2′,2′-difluorodeoxycytidine (gemcitabine) on DNA replication in intact HL-60 cells. Biochem Pharmacol 48:1619-1630, 1994
35. Schy WE, Hertel LW, Kroin JS et al.: Effect of a template-located 2′,2′-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3′-5′exonuclease) fragment. Cancer Res 53:4582-4587, 1993
36. Heinemann V, Xu Y-Z, Chubb S, Sen A et al.: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567-572, 1990
37. Baker CH, Banzon J, Bollinger JM: 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34:1879-1884. 1991
38. Stubbe J: Ribonucleotide reductases. Adv Enzymol 63:349-419, 1990
39. Goz B: The effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells. Pharmacol Rev 29:249-272, 1978
40. Kinsella TJ, Dobson PP, Mitchell JB, Fornace AJ Jr: Enhancement of X-ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 13:733-739, 1987
41. Lawrence TS, Davis MA, Stetson PL, Ensminger WD: The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat Res 123:192-198, 1990
42. Shewach DS, Ellero J, Mancini WR, Ensminger WD: Decrease in TTP pools mediated by 5-bromo-2′-deoxyuridine exposure in a human glioblastoma cell line. Biochem Pharmacol 43:1579-1585, 1992
43. Sinclair WK: The combined effect of hydroxyurea and X-rays on Chinese hamster cells in vitro. Cancer Res 28:190-196, 1992
44. Shewach DS, Hahn T, Chang EY et al.: Depletion of dNTP pools and radiosensitization by difluorodeoxycytidine in HT-29 colon carcinoma cells. Proc Am Assoc Cancer Res 34:418, 1993
45. Lawrence TS, Chang EY, Hahn TM et al.: Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′deoxycytidine. Radiat Res (in press)
46. Terasima T, Tolmach LJ: Variations in several responses of HeLa cells to X-irradiation during the division cycle. Biophys J 3:11-33, 1963
47. Dewey WC, Noel JS, Dettor CM: Changes in radiosensitivity and dispersion of chromatin during the cell cycle of synchronous Chinese hamster cells. Radiat Res 52:373-394, 1972
48. Okayasu R, Bloecher D, Iliakis G: Variation through the cell cycle in the dose-response of DNA neutral filter elution in X-irradiated synchronous CHO-cells. Int J Radial Biol 53:729-747, 1988
49. Sinclair WK: Sensitivity to mitotic delay and stage in the cycle. Curr Topics Radiat Res 7:323-327, 1972
50. Shewach DS, Hahn TM, Chang E et al.: Radiosensitization of HT-29 human colon carcinoma cells after 2 hours exposure to difluorodeoxycytidine. Proc Am Assoc Cancer Res 36:405, 1995
51. Crino L, Scagliotti G, Marangolo M et al.: Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC). A phase II study. Proc Am Soc Clin Oncol 14:352 (abstr 1066), 1995
52. Rich TA, Lokich JJ, Chaffey JT: A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy. J Clin Oncol 3:402-406, 1985